NICE Says Yes To Akcea’s Tegsedi After ‘Improved’ Commercial Offer
Executive Summary
NICE has given the green light to Akcea Therapeutics’ ultra-rare disease treatment Tegsedi (inotersen) after the company offered a better “commercial arrangement.”
You may also be interested in...
NICE Rejects Akcea’s High-Cost Waylivra
Initial knock-back from NICE means Akcea will need to improve commercial offer.
Akcea C-Suite Upheaval’s Reasons Unclear, Firm Set To Take In More Ionis Programs
Akcea terminates top three execs while praising their accomplishments in building up the Ionis spinout. Stock finished the trading day down nearly 20%.
A Win For Alnylam In England As NICE Reverses Onpattro Rejection
Health technology appraisal body NICE now says that Alnylam's innovative gene silencing drug is value for money for the treatment of the rare disease, hereditary transthyretin-related amyloidosis.